Effectiveness and Safety of Rivaroxaban in Prevention of Deep Vein Thrombosis after Major Orthopedic Surgery / 天津医药

ABSTRACT

Objective To evaluate the effectiveness and safety of rivaroxaban or enoxaparin in preventing deep vein thrombosis(DVT) and pulmonary embolism (PE) after major orthopedic surgery. Methods A total of 278 patients underwent major orthopedic surgery, from September 2009 to May 2012, were included in this study. One hundred and forty patients (the average age was 72.7 years, 42.8% were male) were treated with oral rivaroxaban, 10 mg/d. One hundred and thirty-eight patients (the average age was 69.9 years, 39.1%were male) were treated with subcutaneous enoxaparin,40 mg/d. Data were compared between two groups. The ending events included venous thrombosis VTE(DVT and PE), wound complica-tions, re-admission,need for blood transfusion,big and minor bleeding events and death. Results There were no signifi-cant differences in the incidence of VTE, blood transfusions and re- admission rates between two groups. The incidence rates of minor bleeding were 2.1%and 5.8%in two groups. There were no pulmonary embolism, severe bleeding or death in two groups of patients.Conclusion There were no significant differences in the incidence rates of VTE or major bleeding areas in patients with oral treatment of rivaroxaban and enoxaparin.Rivaroxaban was safer with a slightly decrease in minor bleeding and wound complications.